Analyze Diet
Journal of equine veterinary science2026; 106210; doi: 10.1016/j.jevs.2026.106210

Plasma biomarkers of muscle atrophy in senior horses with or without pituitary pars intermedia dysfunction.

Abstract: Muscle atrophy is commonly associated with pituitary pars intermedia dysfunction (PPID), although the pathophysiology is yet to be fully elucidated. Objective: To evaluate muscle atrophy in a population of senior horses and ponies, with and without PPID, and to measure plasma concentrations of circulating factors that might be associated with muscle atrophy, including hormones, metabolites and cytokines. Methods: Cross-sectional study of 35 horses and ponies aged ≥15 years; 14 with PPID and 21 without PPID. Body condition score (BCS; 1-9 scale) and muscle atrophy score (MASS; 4-16 scale) were evaluated, and a range of plasma analytes including total cortisol, aldosterone, insulin-like growth factor-1 (IGF-1), activin A, myostatin, 3-methylhistidine, cytokines and chemokines were measured. Plasma metabolomic profiles were also compared. Results: Body condition score (median [IQR]) was not different (P=0.81) between PPID (6.0 [5.0-6.4]) and non-PPID groups (6.0 [4.7-7.0]), but MASS (median [IQR]) was significantly higher (P<0.001) in the PPID group (7 [5-8]) than the non-PPID group (4 [4-4.5]). Plasma aldosterone (mean ± SD; 54.8±15.9 vs. 37.0±14.4 pg/mL; P=0.002), IGF-1 (265.6±88.4 vs. 195.6±69.7 ng/mL; P=0.020) and 3-methylhistidine (598.9±229.7 vs. 439.8±149.3 nmol/mL; P=0.033) were higher in the PPID group than the non-PPID group. Plasma 3-methylhistidine was positively correlated with MASS score (r=0.54; P<0.001). Conclusions: Horses and ponies with PPID demonstrated higher muscle atrophy scores. This study provides further evidence that muscle atrophy may be specifically associated with PPID and not necessarily just due to aging. However, there was no evidence for many typical biomarkers of muscle atrophy being involved, except for 3-methylhistidine.
Publication Date: 2026-11-15 PubMed ID: 43035136DOI: 10.1016/j.jevs.2026.106210Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This study investigated muscle wasting in older horses and ponies to determine if it is linked to pituitary pars intermedia dysfunction (PPID), a common endocrine disorder in horses, by measuring muscle condition and multiple blood biomarkers related to muscle atrophy.
  • The research compared horses with PPID to those without and identified specific differences, especially in muscle atrophy severity and the presence of certain plasma substances.

Background and Objective

  • Muscle atrophy, or loss of muscle mass, is often seen in senior horses with PPID, but the biological mechanisms causing this have not been clearly understood.
  • The study aimed to evaluate and compare muscle atrophy in aged horses with and without PPID.
  • It also sought to measure levels of hormones, metabolites, and cytokines in the blood that might be linked to muscle wasting.

Methods

  • A cross-sectional study was conducted involving 35 horses and ponies aged 15 years or older.
  • Out of these, 14 were diagnosed with PPID and 21 were without the condition.
  • Researchers assessed body condition using a standardized score (Body Condition Score, BCS; range 1-9) and muscle condition with a Muscle Atrophy Score (MASS; range 4-16).
  • Plasma concentrations of various analytes were measured, including:
    • Total cortisol
    • Aldosterone
    • Insulin-like growth factor-1 (IGF-1)
    • Activin A
    • Myostatin
    • 3-methylhistidine (a marker of muscle protein breakdown)
    • Various cytokines and chemokines
  • Additionally, plasma metabolomic profiles—a broad analysis of metabolites in the blood—were compared between groups.

Results

  • Body Condition Score (BCS) was similar between horses/ponies with PPID (median 6.0) and those without (median 6.0), indicating similar overall body fat and nutritional status.
  • Muscle Atrophy Scores (MASS) were significantly higher in the PPID group (median 7) compared to the non-PPID group (median 4), with this difference being statistically significant (P<0.001). This indicates more severe muscle wasting in the PPID group.
  • Plasma biomarker differences:
    • Aldosterone levels were significantly higher in PPID horses (54.8 pg/mL) compared to non-PPID (37.0 pg/mL), suggesting altered adrenal hormone regulation.
    • IGF-1, a hormone critical for muscle growth and repair, was also elevated in PPID horses (265.6 ng/mL vs. 195.6 ng/mL), which is somewhat unexpected given its anabolic role.
    • 3-methylhistidine levels were greater in PPID horses (598.9 nmol/mL) than non-PPID (439.8 nmol/mL), indicating increased muscle protein breakdown in PPID animals.
    • Notably, plasma 3-methylhistidine levels correlated positively with the muscle atrophy score (r=0.54), supporting its role as a biomarker of muscle wasting.
  • No meaningful differences or associations were found in other typical muscle atrophy biomarkers such as myostatin or activin A, or many cytokines measured.

Conclusions and Implications

  • The study confirmed that horses and ponies with PPID experience significantly more muscle atrophy compared to similarly aged individuals without PPID, indicating muscle wasting is linked specifically to the disease rather than aging alone.
  • The increase in plasma 3-methylhistidine is particularly relevant, as it provides a measurable blood biomarker reflecting muscle protein breakdown associated with PPID-related muscle atrophy.
  • The elevation of IGF-1 and aldosterone suggests complex endocrine changes in PPID, although their exact roles in muscle atrophy require further investigation.
  • The lack of changes in other common muscle atrophy biomarkers suggests that the mechanisms of muscle wasting in PPID may differ from other muscle wasting diseases.
  • These insights improve understanding of PPID-associated muscle loss and could aid in monitoring and developing therapies to prevent or treat muscle atrophy in affected senior horses.

Cite This Article

APA
Galinelli NC, Erdody ML, Bamford NJ, Mackenzie SA, Harris PA, Sillence MN, Bailey SR. (2026). Plasma biomarkers of muscle atrophy in senior horses with or without pituitary pars intermedia dysfunction. J Equine Vet Sci, 106210. https://doi.org/10.1016/j.jevs.2026.106210

Publication

ISSN: 0737-0806
NlmUniqueID: 8216840
Country: United States
Language: English
Pages: 106210
PII: S0737-0806(26)00444-2

Researcher Affiliations

Galinelli, N C
  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Erdody, M L
  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Bamford, N J
  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Mackenzie, S A
  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia.
Harris, P A
  • Equine Studies Group, Waltham Petcare Science Institute, Mars Horsecare, Leicestershire, LE14 4RT, UK.
Sillence, M N
  • School of Biology and Environmental Science, Queensland Universtiy of Technology, Brisbane, Queensland, Australia.
Bailey, S R
  • Melbourne Veterinary School, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: bais@unimelb.edu.au.

Conflict of Interest Statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Martin Sillence reports financial support was provided by Australian Research Council. Martin Sillence reports financial support was provided by Boehringer Ingelheim Vetmedica GmbH. Martin Sillence reports financial support was provided by Mars Petcare UK. Simon Bailey reports a relationship with Boehringer Ingelheim Vetmedica GmbH that includes: consulting or advisory. Patricia Harris reports a relationship with Mars Petcare UK that includes: consulting or advisory. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Citations

This article has been cited 0 times.